Concepedia

Yan Sun

YS

18

Publications

1K

Citations

15

H-Index

1994

Active since

Affiliations

AbbVie (United States)(Current)

Chinese Academy of Medical Sciences & Peking Union Medical College

The University of Texas MD Anderson Cancer Center

Monash University

Peter MacCallum Cancer Centre

Yan Sun is an author at AbbVie (United States) specializing in medicine, oncology, and pharmacotherapy.

ORCID

Top concepts

Publications per year

1994–2024

18

Publications

18

Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Vinod Pullarkat, Norman J. Lacayo, Elias Jabbour et al. · Cancer Discovery · 2021 · 270 citations · Full text

[Results of randomized, multicenter, double-blind phase III trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients].

Jinwan Wang, Yan Sun, Qitao Yu et al. · PubMed · 2005 · 147 citations

Outcomes in Patients with Poor-Risk Cytogenetics with or without <i>TP53</i> Mutations Treated with Venetoclax and Azacitidine

Daniel A. Pollyea, Keith W. Pratz, Andrew H. Wei et al. · Clinical Cancer Research · 2022 · 137 citations · Full text

Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine

Hartmut Döhner, Keith W. Pratz, Courtney D. DiNardo et al. · Blood · 2024 · 108 citations · Full text

Patient subgroup identification for clinical drug development

Xin Huang, Yan Sun, Paul Trow et al. · Statistics in Medicine · 2017 · 60 citations · Full text

Rows per page

1–5 of 18